Growth ⏱ Half-life: Approximately 2 hours, supporting multiple daily administrations in pulsatile protocols.

Ipamorelin

Ipamorelin (Growth Hormone Secretagogue)

Buy from $39.99 →
Half-Life
Approximately 2 hours, supporting multiple daily administrations in pulsatile protocols.
Mol. Weight
711.85 g/mol

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue known for its remarkable selectivity. Among the GHRP (Growth Hormone Releasing Peptide) family, it stands out for stimulating growth hormone release while having minimal effects on other hormonal axes.

Research Applications

Research contexts include GH axis stimulation (selective, clean GH release), body composition studies, bone density research, recovery and tissue repair, and age-related GH decline models.

Dosage Information (Research Use)

Common research protocols: 100-300 mcg per administration, 1-3 times daily. Frequently paired 1:1 with CJC-1295 (Mod-GRF). Research use only.

Reconstitution & Handling

Standard BAC water reconstitution. Dissolves quickly and clearly.

Half-Life & Pharmacokinetics

Approximately 2 hours, supporting multiple daily administrations in pulsatile protocols.

Reported Observations in Literature

Generally well-tolerated in research. Mild hunger increase and transient head rush reported. Notably lacks the significant cortisol and prolactin elevation seen with GHRP-6 and GHRP-2.

Key Research References

  • Raun K, et al. “Ipamorelin, the first selective growth hormone secretagogue.” Eur J Endocrinol. 1998
  • Johansen PB, et al. “Ipamorelin: a new growth-hormone-releasing peptide.” J Endocrinol. 1999

How Ipamorelin Works

Ipamorelin is a pentapeptide growth hormone secretagogue that acts through the ghrelin/GHS (growth hormone secretagogue) receptor. Its selectivity distinguishes it from other GHRP peptides — it stimulates GH release with minimal impact on cortisol, prolactin, or ACTH levels. This selectivity results from specific receptor binding kinetics that favor somatotroph activation over corticotroph or lactotroph stimulation.

Research Findings

Considered the most selective GHRP available for research. The clean GH-release profile without cortisol or prolactin elevation makes it preferred in research protocols where hormonal specificity matters. Synergistic with GHRH analogs (CJC-1295) — the combination produces GH release greater than either compound alone.

Dosage & Administration

Common research protocols: 100-300 mcg per administration, 1-3 times daily. Frequently paired 1:1 with CJC-1295 (Mod-GRF). Research use only.

Safety & Side Effects

Generally well-tolerated in research. Mild hunger increase and transient head rush reported. Notably lacks the significant cortisol and prolactin elevation seen with GHRP-6 and GHRP-2.

Important: All safety information is derived from published research, primarily animal studies. No controlled human clinical trial data exists unless explicitly noted. This compound is sold for research purposes only.

Quick Facts

Sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2
Molecular Weight 711.85 g/mol
Half-Life Approximately 2 hours, supporting multiple daily administrations in pulsatile protocols.
Available Sizes 2mg, 5mg
Storage Lyophilized: -20°C. Reconstituted: 2-8°C, use within 21 days.

Key Research References

  • Raun K, et al. "Ipamorelin, the first selective growth hormone secretagogue." Eur J Endocrinol. 1998
  • Johansen PB, et al. "Ipamorelin: a new growth-hormone-releasing peptide." J Endocrinol. 1999

Get Ipamorelin from SourcePeptides

Third-party tested • Research-grade purity • Fast US shipping

Shop Now →

Related Peptides

View all →
Unmodified C-terminal fragment of human growth hormone (amino acids 176-191) studied for lipolytic activity.
Growth
First 29 amino acids of native GHRH — the original synthetic GHRH analog used in GH deficiency research…
Growth
Myostatin pathway decoy receptor researched for increasing lean mass in muscle-wasting conditions.